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Abstract
Prior to the genome-wide association era, candidate gene studies were a major approach in 
schizophrenia genetics. In this invited review, we consider the current status of 25 historical 
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candidate genes for schizophrenia (e.g., COMT, DISC1, DTNBP1, and NRG1). The initial study 
for 24 of these genes explicitly evaluated common variant hypotheses about schizophrenia. Our 
evaluation included a meta-analysis of the candidate gene literature, incorporation of the results of 
the largest genomic study yet published for schizophrenia, ratings from informed researchers who 
have published on these genes, and ratings from 24 schizophrenia geneticists. On the basis of 
current empirical evidence and mostly consensual assessments of informed opinion, it appears that 
the historical candidate gene literature did not yield clear insights into the genetic basis of 
schizophrenia. A likely reason why historical candidate gene studies did not achieve their primary 
aims is inadequate statistical power. However, the considerable efforts embodied in these early 
studies unquestionably set the stage for current successes in genomic approaches to schizophrenia.
Keywords
schizophrenia; genetics; candidate gene; review; meta-analysis
Introduction
In this review, we consider the current status of candidate genes for schizophrenia that were 
prominent in the literature prior to the genome-wide association study (GWAS) era. This 
review was invited by Prof Julio Licinio, the editor of Molecular Psychiatry.
Due to the high heritability of schizophrenia1, there have been many efforts to discover the 
causative genetic factors, and candidate gene studies have been a major approach. For 
example, the SZGene database 2 (obtained 11/2009) listed 1406 candidate gene papers 
investigating over 700 genes. In these studies, one or more genetic markers in genes 
hypothesized to be involved in the etiology of schizophrenia were genotyped in cases with 
schizophrenia and controls. Prior to the advances brought about by the Human Genome 
Project3 and the International HapMap Project 4, it was difficult and expensive to genotype a 
comprehensive list of genetic variants in a genomic region. Investigators thus tended to 
genotype a few genetic markers in a candidate gene selected based on prevailing theories of 
the etiology of schizophrenia (e.g., antipsychotic pharmacology) or positional candidate 
genes from linkage or cytogenetic studies.
The candidate gene strategy had a few notable successes in identifying genetic variation for 
other complex diseases. Influential examples included replicated associations of 
Alzheimer’s disease with common variation in APOE 5 and alcohol dependence with 
common variants in alcohol metabolic genes. 6 It was thus not unreasonable to hope that 
similar studies might work for schizophrenia. Realization of this expectation proved 
difficult. A pattern emerged whereby an initial claim of association for a seemingly 
plausible, even exciting, candidate gene for schizophrenia was followed by a mixed pattern 
of non-replications and replication. Thus, candidate gene association studies for 
schizophrenia became controversial. 7–10
The goal of this review is to evaluate the current status of historical candidate genes for 
schizophrenia. The motivation is straight-forward: there are hundreds of papers on these 
genes, several of these genes have motivated considerable biological experimentation, and 
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as recent large-scale studies have expanded our knowledge base, it is reasonable to review 
this topic. Early candidate gene studies evaluated tens of genetic markers in hundreds of 
subjects and more recent studies conducted genome-wide comparisons of millions of genetic 
markers in tens of thousands of subjects. The largest published study is of 34,000 cases from 
the Psychiatric Genomics Consortium, PGC) which identified 108 genome-wide significant 
loci. 11
Almost all of these historical candidate gene studies evaluated the role of common variation 
(one part of a spectrum of variants involved in schizophrenia). Our evaluation includes: (a) 
meta-analysis of candidate gene studies, (b) PGC schizophrenia mega-analysis results,11 (c) 
expert evaluations from researchers on specific candidate genes, and (d) survey ratings from 
schizophrenia genomics investigators. The latter two approaches are not “scientific” in a 
strict sense, but rather provide a general guide to the “significance” and “impact” that the 
earlier findings currently have in the field.
Methods
We selected 25 genes prominent in the pre-GWAS era. The first schizophrenia GWAS 
appeared in 2007 but, given that many candidate gene association studies were published in 
2008, we evaluated candidate gene studies published in calendar year 2008 or earlier. The 
25 genes we selected were either featured in reviews of the genetics of 
schizophrenia 10, 12–14 or were highly studied (≥20 papers recorded in SZGene). The genes 
and the rationale for being a candidate gene for schizophrenia are given in Table 1. We 
continued several important assumptions made by virtually all candidate gene studies (see 
Limitations). First, these studies evaluated “schizophrenia” as a dichotomous entity. Second, 
as with the primary studies, we assumed that genetic variants act on the gene it was in or 
near. This assumption is crucial and will be inaccurate for a currently unknown proportion 
of genetic variants. Third, as discussed below, almost all of these studies evaluated common 
genetic variation.
We evaluated these 25 historical candidate genes for schizophrenia in four ways. First, we 
conducted fixed-effects meta-analyses for all genetic markers in these 25 genes using 
summary data on subjects of European ancestry in the SZGene database. 2 Second, we 
included PGC results for schizophrenia (9.5 million markers in 34,241 cases, 45,604 
controls, and 1,235 trios followed by replication analyses of 263 SNPs in 1,513 cases and 
66,236 controls). 11 We report the results for the same SNP appearing in SZGene and for the 
SNP with the smallest P-value in a gene (± 25 kb).
Third, we elicited perspectives from “informed investigators” who had published most 
extensively on or were the original or firmest proponents of a particular candidate gene in 
schizophrenia. These individuals were identified using PubMed searches: (gene [All Fields] 
OR “protein name” [All Fields]) AND (“schizophrenia” [MeSH Terms] OR “schizophrenia” 
[All Fields]). Informed investigators were contacted to request their summary judgment of 
the current status of one particular gene as a genetic risk factor for schizophrenia (1=very 
unlikely and 5=very likely). Genetic risk could refer to common, uncommon, rare, private, 
or de novo genetic variation. A draft of Table 2 was supplied upon request. Informed 
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investigators were given the opportunity to include text in the Supplement to explain their 
rating.
Fourth, we obtained perspectives from “schizophrenia geneticists”. We used principal 
investigators from the PGC schizophrenia working group11 as a convenience sample. We 
obtained responses from 24 investigators for summary judgments using the same rating 
scheme as for the informed investigators. Many of these investigators study common, 
uncommon, rare, private, or de novo genetic variation.
Results
Table 1 summarizes 25 historically important candidate genes for schizophrenia. For 24 of 
25 genes, the initial study conducted genotyping to evaluate the impact of common genetic 
variation on risk for schizophrenia. Some candidate genes were selected because of rare 
genetic events (e.g., COMT, PRODH, and ZDDHC8 are located in the 22q11 deletion CNV) 
but the study evaluate common genetic variation rather than rare variation. The DISC1 study 
genotyped rare variation in a Scottish pedigree. The key findings for three genes were 
unimpressive for schizophrenia per se but presented somewhat more significant findings for 
putative endophenotypes (CHRNA7 and COMT) or a broadly inclusive set of psychiatric 
disorders (DISC1). Eleven genes were positional candidates based on genome-wide linkage 
or structural variation (CHRNA7, COMT, DAO, DAOA, DISC1, DTNBP1, NOTCH4, NRG1, 
PPP3CC, PRODH, and ZDHHC8). Eight genes derived from a hypothesis about the 
etiology of schizophrenia based on pharmacology (AKT1, DRD2, DRD3, DRD4, GRM3, 
HTR2A, SLC6A3, and SLC6A4). Six genes were from miscellaneous hypotheses (APOE, 
BDNF, KCNN3, MTHFR, RGS4, and TNF).
Many of the reported common variant SNP or haplotype relative risks were exceptionally 
large: often >1.5 and >2 for DRD3, HTR2A, MTHFR, NRG1, and PRODH. Rigorous control 
for multiple testing of genetic markers, haplotypes, and/or phenotypes was evident in one 
study (ZDHHC8). None of the P-values in the primary studies were genome-wide 
significant 15 (P<5x10−8), and most were not notable after correction for the number of 
SNPs genotyped.
Figure 1 shows the number of times that each gene or its protein product co-occurred with 
schizophrenia in a paper indexed by PubMed per year. This serves as a rough metric for the 
importance/impact of a gene for the schizophrenia research community. For eight genes, the 
numbers of studies increased with time (APOE, BDNF, CHRNA7, COMT, DISC1, DRD2, 
HTR2A, and NRG1). Four genes peaked and then tapered off (DAO, DAOA, DTNBP1, and 
RGS4). For 13 genes, there have been relatively few reports (AKT1, DRD3, DRD4, GRM3, 
KCNN3, MTHFR, NOTCH4, PPP3CC, PRODH, SLC6A3, SLC6A4, TNF, and ZDHHC8).
Table 2 provides four evaluations for each historical candidate gene for schizophrenia. The 
first evaluation is a meta-analysis of candidate gene association studies in SZGene published 
in 2008 or earlier showing the most-studied genetic marker per gene (Table S1 shows results 
for all markers). We have previously shown that the candidate gene studies in SZGene had 
small samples and poor coverage of common genetic variation.16 No finding is near 
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genome-wide significance 15 (P<5x10−8), and all P-values for this evaluation fall short by a 
factor of 10,000 or more. None is notable even on a gene-wise basis (which many would 
consider inappropriately liberal).
The second evaluation reports the results from the large PGC mega-analysis for 
schizophrenia. 11 We report results for the same SZGene polymorphisms (if available) plus 
the smallest P-value in the gene (±25 kb). The PGC and SZGene results agree on the 
absence of evidence of association for most of these genes (21/25). Four genes (DRD2, 
GRM3, NOTCH4, and TNF) are genome-wide significant in the PGC analysis, but were not 
implicated by the SZGene meta-analysis. The lack of association for NOTCH4 and TNF in 
the candidate gene literature is notable given that these genes are in the major 
histocompatibility complex (MHC). The MHC contains the most significant association 
common variant association (P=3.5x10−31) and the second largest OR (1.2) for 
schizophrenia. 11 Due to extensive linkage disequilibrium, the MHC contains thousands of 
genome-wide significant associations extending over 7 Mb. Indeed, there are over 60 
genome-wide significant associations ±25 kb of NOTCH4 and four ±25 kb of the small TNF 
gene (2.8 kb). 11
The third evaluation was a rating by informed investigators for 12 genes. These individuals 
introduced the gene into the literature or had published extensively on it. The informed 
investigators provide fuller explanations for their rankings in the Supplement. Five genes 
(AKT1, CHRNA7, DISC1, DRD2, and HTR2A) were rated as highly likely to be a genetic 
risk factor for schizophrenia (rating ≥4 on a 1–5 scale). With the exception of DRD2, none 
of the informed ratings ≥4 is supported by empirical results from the older SZGene or the 
newer PGC mega-analysis.
The fourth evaluation consisted of ratings from 24 schizophrenia geneticists. The 
distribution of ratings is provided in Figure S2. The mean ratings were ≥4 for only DRD2 
and GRM3. The mean ratings were discordant with those from informed investigators for 
AKT1, CHRNA7, DISC1, and HTR2A.
Discussion
Our knowledge of the genetic architecture of schizophrenia – the number of loci, allele 
frequencies, genotypic relative risks, and modes of action – has grown significantly in the 
past year. The largest GWAS to date suggests that schizophrenia is associated with many 
common genetic variants of small effect sizes. 11 Several rare CNVs have genotypic relative 
risks in the 5–20 range. 17 Rare exonic variants of stronger effect do play a role, but it now 
appears unlikely that schizophrenia has a genetic architecture dominated by such 
variants. 18, 19 A direct comparison found that common genetic variation accounted for far 
more of the variance in liability to schizophrenia than rare copy number variation or rare 
deleterious exonic variation.18
Given the importance of common variation in the etiology of schizophrenia and that 24 of 
25 historical candidate genes for schizophrenia explicitly posited and evaluated the role of 
common variation, it is timely to assess the contributions of this literature to our knowledge 
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of schizophrenia. With the advantages of hindsight (and noting that the authors of this 
review conducted many candidate gene studies including two in Table 1 20, 21), we offer a 
number of explanatory hypotheses regarding this literature.
Historical candidate genes for schizophrenia in light of current empirical results
First, it is now clear that historical candidate gene association studies for common genetic 
variation had grossly inadequate statistical power. For example, a candidate gene study of 
1,000 cases and 1,000 controls has 0.03% power 22 to detect a genotypic relative risk (GRR) 
of 1.15 (assuming a log-additive model, lifetime prevalence=0.007, minor allele 
frequency=0.3, and α=5x10−8). A GRR of 1.15 is large for schizophrenia, and only 10 of 
128 SNPs 11 reaching genome-wide significance had GRR > 1.15. When power is so low, 
the probability that a “significant” finding is a false positive is overwhelming. 23, 24
Second, the largest GWAS to date had essentially 100% power to identify common genetic 
variants with GRR > 1.15 (minor allele frequency > 0.10) or GRR > 1.19 (minor allele 
frequency > 0.05). We can thus exclude common genetic effects akin to those for APOE and 
Alzheimer’s disease (i.e., GRR of 3.7 for APOE*ε4 vs. ε3). 25 We can also conclude that the 
GRRs reported in many of the 24 common variant studies in Table 1 (often >1.5 and >2 for 
five genes) are inconsistent with what we now know about GRRs for common variation 
(Table 2, often for the same genetic marker reported in the initial study). Some common 
variants in Table 2 (e.g., the KCNN3 CAG repeat or complex haplotypes in NRG1) may not 
have been well-captured in SNP arrays; however, this criticism is mitigated by the lack of 
evidence from the SZGene meta-analyses for the same variants.
Third, even before the current generation of large genomic studies for schizophrenia, it was 
reassuring to note that candidate gene meta-analyses by other authors (Table S2) 26–41 and 
our SZGene meta-analyses (Table 2) were converging on the null. This is important because 
the candidate gene literature for common variation in schizophrenia is often believed to be 
replete with false positive claims: this generality is not supported by meta-analysis.
Fourth, the largest and most carefully conducted schizophrenia common variant association 
study does not provide empirical support for 21 of the 25 historical candidate genes as 
genetic risk factors for schizophrenia. 11 Two historical candidate genes (DRD2 and GRM3) 
have genome-wide significant evidence for common variant association with 
schizophrenia 11 although the candidate gene literature did not support these associations. 
Two additional candidate genes (TNF and NOTCH4) have genome-wide significant 
associations with schizophrenia. 11 These genes are in the extended MHC, a complex region 
with high gene density and extensive linkage disequilibrium, and the MHC-schizophrenia 
association may not implicate these genes. The candidate gene literature missed these 
associations although these should have been the most accessible common variant findings: 
the MHC was the first genome-wide significant GWAS signal for schizophrenia 42–44 and 
11% of high-quality SNPs (6,570 of 57,891) in the extended MHC region exceeded genome-
wide significance. 11 These false negatives from the pre-GWAS era likely resulted from 
extremely low statistical power and limited genotyping.
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Fifth, one historical candidate gene (DISC1) studied a rare genetic event, the t(1;11) 
(q42.1;q14.3) translocation in a Scottish pedigree where the propositus did not have 
schizophrenia. The genetic linkage results in this pedigree point to a broad phenotype (LOD 
7.1 for recurrent major depression, bipolar disorder, or schizophrenia). The status of DISC1 
is controversial despite its entry into the literature nearly 15 years ago 45 (see also a 
rebuttal 46). The most critical issue is that no other genetic study has independently 
implicated DISC1 (i.e., met contemporary significance thresholds for rare exonic variation, 
rare CNVs, or common variation). 11, 18, 19, 47, 48 In contrast, many other rare variant 
associations have genetic replication evidence. For example, early-onset Alzheimer’s 
disease is caused by rare mutations in APP, PSEN1, and PSEN2.49 Unlike the singular 
DISC1 event, these associations are highly compelling as they replicate in many different 
pedigrees (90 families for APP, 405 for PSEN1, and 22 for PSEN2, see URLs). Similarly, 
the CNV associations for autism and schizophrenia replicate in large samples worldwide. 17
In conclusion, the current evidence from large and carefully conducted studies of genetic 
variation does not support the idea that the historical candidate gene literature led to robust 
and replicable genetic findings with the capacity to provide insights into the etiology of 
schizophrenia. Most genes (24 of 25) evaluated common variant hypotheses: the large effect 
sizes posited by initial studies were not confirmed, and four common variant associations 
that now meet genome-wide significance were missed. These conclusions have an important 
qualifier. Knowledge of the genetic basis of schizophrenia is incomplete but rapidly 
growing. Historically large studies were published in 2014, and considerable expansions of 
sample sizes for common and rare variant analyses are in progress. Some genes in Table 2 
could become notable in the future.
Alternative perspectives on historical candidate genes for schizophrenia
The opinions of experts play a role in science particularly when there are few hard data, and 
have been important in psychiatry. 50 The prominence of some historical candidate genes for 
schizophrenia has increased despite a lack of strong support from genetic studies (Figure 1). 
Thus, we also surveyed opinions on these genes. First, for 12 genes, we obtained ratings 
from informed investigators (i.e., those who introduced a candidate gene into the literature 
or who published extensively on it, Table 2). We point readers to the Supplement for further 
explanations from the informed investigators. The informed investigator ratings agreed with 
the PGC results for seven genes. For five genes (AKT1, CHRNA7, DISC1, DRD2, and 
HTR2A), the informed investigator rating was high (a rating ≥4 on a 1–5 scale). For one of 
these five (DRD2), the PGC results concur. For the remaining four genes, the informed 
investigator ratings ≥4 were different from empirical results.
Second, we obtained ratings from 24 schizophrenia geneticists. The mean ratings were ≥4 
for only DRD2 and GRM3. The mean ratings were inconsistent with those from informed 
investigators for AKT1, CHRNA7, DISC1, and HTR2A. Note that all ratings could 
incorporate any type of genetic variation. In general, we found that empirical data and 
opinion agreed for most of the 25 candidate genes, and the discrepancies for AKT1, 
CHRNA7, DISC1, and HTR2A stand out. Several informed investigators address this issue 
and believe that genetic results that do not meet widely accepted standards for significance 
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in genetics or which lack replication can be augmented by biological data (Supplement). To 
this view, biological plausibility can provide salience to chance-level genetic results.
We contend that this “biological validation” argument is weak, subjective, prone to incorrect 
decisions, and liable to divert downstream research efforts by emphasizing the wrong 
targets. First, as documented in this paper, biology-driven candidate gene studies have not 
been particularly useful. Second, because we understand so little of the pathogenesis of 
schizophrenia, we have no biological gold standards or first principles. Put simply, there is 
neither a biology that we can demand of a ‘”true” associated gene nor a biology that is 
inconsistent with a “false” gene. Third, how then can we assess the validity of the biological 
connection being made? For genetics to achieve its goal of providing secure entry points 
into the biology of schizophrenia, findings must stand on their own merits without reference 
to other biological hypotheses or data. To do otherwise inevitably leads to circular reasoning 
(i.e., speculative biological supported by weak genetics supported by biological 
speculation).
Fourth, the criterion of biological salience is surprisingly inclusive. A large fraction of 
human genes are of legitimate interest to an integrative neuroscientist: depending on 
inclusion criteria, ⅓ to ⅔ of human genes are of biological interest (Figure 2). Genomic 
studies can test millions of hypotheses –hundreds of genetic markers will have P-values in 
the 10−5 to 10−7 range from the play of chance. These “intriguing” genetic markers will, 
merely by chance, often be located near a biologically “cool” gene. This is a meaningless 
coincidence until proven otherwise by genetic evidence.
Fifth, this argument is counter to best practices in human genetics that demand rigorous 
significance thresholds and replication. 51–55 For GWAS, the 5x10−8 threshold is nearly 
universally accepted. For rare variants of strong effect, a recent Nature paper summarized 
the recommendations of an NHGRI working group: 56 (a) “we emphasize the critical 
primacy of robust statistical genetic support for the implication of new genes, which may 
then be supplemented with ancillary experimental or informatic evidence supporting a 
mechanistic role”; (b) “Just as for genome-wide association studies of common variants, 
replication of newly implicated disease genes in independent families or population cohorts 
is critical supporting evidence, and in most cases essential for a novel gene to be regarded as 
convincingly implicated in disease”; and (c) “Without rigorous standards we risk an 
acceleration of false-positive reports of causality, which would impede the translation of 
genomic research findings into the clinical diagnostic setting and hinder biological 
understanding of disease”.
Sixth, this argument is not accepted by many journals. Nature Genetics requires: “the 
genetic and statistical evidence for association should be sound. Molecular biological 
evidence for a functional variant is desirable in addition to, but will not substitute for, sound 
genetic evidence.” 57 PLoS Genetics states: “genetic arguments should stand on their 
own”. 58
Finally, we note that invoking the biological argument is unnecessary. If statistical 
significance is marginal or if replication is required, then a more definitive study should be 
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designed and conducted in order to falsify the hypothesis. In many instances, this is 
achievable via collaboration and may be difficult for rarer genetic variants. We believe that 
schizophrenia genetics needs secure associations (significant beyond chance with precise 
replication) in order for genomic knowledge to be used as the essential anchor for 
understanding the biological basis of schizophrenia. Best practices in 2014 are thus very 
different from 2004. For example, the AKT1 paper appeared in Nature Genetics in 2004 59 
with a considerable amount of biological and mouse model data but the genetic data are a 
SNP P-value of 0.05 (uncorrected for five genotyped SNPs) with no replication data.
Limitations - Can any historical candidate gene be formally excluded?
We have been careful to state that the current genomic evidence is inconsistent with an 
association for a particular gene. This is an evolving area, and it is possible that genes not 
now associated with schizophrenia will transition to significance with on-going expansions 
of sample sizes for common and rare variation. None of the historical candidate genes can 
be unequivocally excluded as a genetic risk factor for schizophrenia. However, we can state 
with high confidence that the large common variant genetic effects originally reported in 
many initial candidate gene studies are highly unlikely to be true.
Moreover, the location of some associations could provide a false clue, as genetic 
associations can act over long genomic distances – however, this assumption was made in 
the primary studies too. All current genomic technologies may miss some important types of 
genetic variation that play an etiological role.
It can also be argued that the genetic models used in the current generation of genomic 
studies for schizophrenia are inappropriate, that models should incorporate gene-
environment, gene-gene, or even gene-gene-gene interactions. In a similar vein, it is possible 
that analyses that attempt to identify heterogeneity within the “schizophrenia” construct will 
prove informative. These hypotheses and alternative conceptualizations have merit and are 
now being investigated. Conducting these studies to a high standard is very difficult, and 
require unswerving adherence to accepted standards: thorough evaluation of bias, rigorous 
statistical significance thresholds, and replication are essential.
Conclusion
In summary, the current empirical evidence strongly supports the idea that the historical 
candidate gene literature yielded no robust and replicable insights into the etiology of 
schizophrenia. Even so, it is fair to note that these early studies unquestionably set the stage 
for the current era of genomic discovery for schizophrenia. These foundational efforts were 
a necessary step toward a better understanding of schizophrenia as a biological trait.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Candidate gene publications per gene and per year. For each gene, the number of 
publications is indicated on the Y-axis, and the year is the X-axis. The data shown are from 
a PubMed query: (gene [All Fields] OR “protein name”[All Fields]) AND (“schizophrenia”
[MeSH Terms] OR “schizophrenia”[All Fields]). The goal of this PubMed query was to 
provide a rough gauge of the impact of a candidate gene on the field (which differs from the 
“pre-GWAS” column in Table 1).
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Figure 2. How many biologically interesting human genes are there?
This bioinformatic analysis addressed the question: how many human genes are of 
legitimate interest to an integrative neuroscientist or psychiatric geneticist? (A) We 
intersected 19,304 gene models from GENCODE (v17, “KNOWN” or “protein_coding”) 
with multiple data sources. Some genes can be in multiple categories. (B) Summary 
statistics (1=in set, 0=not in set): 35.6% of all genes are in classes A or B (=6869/19304), 
and 61.4% of all genes are in classes A, B, or C (=11849/19304). These numbers are 
conservative as adding “expression in brain at any developmental stage” would increase the 
numbers further. Thus, sizable proportions of all genes are of potential interest to a biologist. 
Biological interest is an imprecise criterion for the salience of a finding.
Farrell et al. Page 16
Mol Psychiatry. Author manuscript; available in PMC 2015 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Farrell et al. Page 17
Table 1
Candidate genes of historical importance in schizophrenia research
Gene Product Reviews Pre-GWAS Rationale
AKT1 v-akt murine thymoma viral oncogene homolog 1 2 13 Mood disorder pharmacology 59
APOE Apolipoprotein E 1 32 Implicated in Alzheimer’s disease 75
BDNF Brain-derived neurotrophic factor 0 40 Neurodevelopment hypothesis 76
CHRNA7 Cholinergic receptor, nicotinic, α7 1 12 Linkage analysis 77
COMT Catechol-O-methyltransferase 4 81 22q11 CNV 78
DAO D-amino-acid oxidase 2 10 Linkage analysis, glutamate hypothesis 79
DAOA D-amino acid oxidase activator 3 27 Linkage analysis, glutamate hypothesis 79
DISC1 Disrupted in schizophrenia 1 3 22 Translocation in a pedigree 80
DRD2 Dopamine receptor D2 1 67 Antipsychotic pharmacology 81
DRD3 Dopamine receptor D3 2 71 Dopamine hypothesis 20
DRD4 Dopamine receptor D4 0 45 Antipsychotic pharmacology 82
DTNBP1 Dystrobrevin binding protein 1 3 32 Linkage analysis 83
GRM3 Glutamate receptor, metabotropic 3 1 15 Glutamate hypothesis 21
HTR2A Serotonin receptor 2A 2 57 Antipsychotic pharmacology 84
KCNN3 Potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 3
0 23 Discovery of a CAG repeat 85
MTHFR Methylenetetrahydrofolate reductase 0 20 Psychiatric symptoms with MTHFR 
dysfunction 86
NOTCH4 Notch 4 0 24 Linkage analysis 87
NRG1 Neuregulin 1 3 41 Linkage analysis 88
PPP3CC Protein phosphatase 3, catalytic subunit, γ isozyme 1 9 Linkage analysis/mouse phenotype 89
PRODH Proline dehydrogenase (oxidase) 1 3 10 22q11 CNV (incorrectly called “PRODH2” 90
RGS4 Regulator of G-protein signaling 4 3 22 Differential expression in cases 91
SLC6A3 Dopamine transporter 0 22 Dopamine hypothesis 92
SLC6A4 Serotonin transporter 1 32 Implicated in mood disorders 93
TNF Tumor necrosis factor 0 21 Immune hypothesis 94
ZDHHC8 Zinc finger, DHHC-type 8 2 9 22q11 CNV 95
Reviews: the number of times a gene was in any of four selected reviews of schizophrenia genetics circa 2005. 10, 12–14 Pre-GWAS: the number 
of schizophrenia candidate gene papers studying this gene in calendar year 2008 or earlier. 2, 16 Rationale: the stated explanation for considering 
this gene as a candidate gene for schizophrenia according to the original publication. With the exception of DISC1, all studies evaluated common 
variant hypotheses.
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